amrubicin

Subscribe to Selected New Research on amrubicin

59 relevant articles (6 outcomes, 25 trials/studies) found for this Bio-Agent

Description: structure in first source; a 9-amino-anthracycline antibiotic

Also Known As:

(7S,9S)-9-acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride; SM 5887; SM-5887; amrubicin hydrochloride

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Aromatic Hydrocarbons: 115

Aromatic Polycyclic Hydrocarbons: 581

Naphthacenes

Anthracyclines: 1290

amrubicin: 59

Polycyclic Compounds: 58

Aromatic Polycyclic Hydrocarbons: 581

Aminoglycosides: 1075

Anthracyclines: 1290

amrubicin: 59

Experts

1.	Fukuoka, Masahiro: 5 articles (10/2007 - 08/2005)
2.	Saito, Hideyuki: 3 articles (02/2008 - 02/2006)
3.	Hamada, Akinobu: 3 articles (02/2008 - 02/2006)
4.	Sasaki, Ji-ichiro: 3 articles (02/2008 - 02/2006)
5.	Okamoto, Isamu: 3 articles (10/2007 - 02/2006)
6.	Negoro, Shunichi: 3 articles (08/2007 - 08/2005)
7.	Yana, Takashi: 3 articles (06/2007 - 08/2005)
8.	Sugiura, Takahiko: 3 articles (06/2007 - 08/2005)
9.	Takada, Minoru: 3 articles (06/2007 - 08/2005)
10.	Ariyoshi, Yutaka: 3 articles (06/2007 - 08/2005)

Related Diseases

1.	Small Cell Carcinoma (Small Cell Lung Cancer) 03/01/2006 - "A case of small-cell lung cancer effectively treated by bi-weekly administration of amrubicin]" 08/01/2007 - "PURPOSE: We conducted a multicenter phase II study of amrubicin, a novel 9-aminoanthracycline, to evaluate its efficacy and safety in patients with non-small-cell lung cancer (NSCLC)" 08/01/2007 - "Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study." 06/01/2007 - "Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study." 12/01/2006 - "Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 01/01/1989 - "Compared with ADR, SM-5887 was statistically more effective in five tumors (one breast, one lung and three gastric), equal in two tumors (two gastric), and less potent in two tumors (one lung and one gastric)" 01/01/1989 - "When the human tumors were implanted sc in female athymic mice (BALB/c, nu/nu) and their volume reached 100-300 mm3, SM-5887 and ADR were injected iv. All nine human tumors tested showed statistically significant responses to SM-5887, and 7 of them were strongly suppressed in their growth by SM-5887 so that minimum T/C values were less than 30% at the maximum tolerated dose (MTD, 25 mg/kg) with a single iv injection" 03/01/2007 - "Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo." 08/01/2003 - "Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline]" 10/01/1998 - "Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin." Get all the results and reference details, order at left...
3.	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/01/2001 - "demonstrating that amrubicin hydrochloride was very effective in the treatment of non-Hodgkin's lymphoma" 11/01/2001 - "A late phase II clinical trial of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, was conducted at 14 institutions nationwide, in patients with non-Hodgkin's lymphoma" 11/01/2001 - "In conclusion, these results indicate that amrubicin hydrochloride is an effective agent as a component of combination chemotherapy for non-Hodgkin's lymphoma." 01/01/1999 - "In phase II trials, amrubicin has shown activity equivalent to that of doxorubicin on non-Hodgkin's lymphoma, response rates exceeding 20% on non-small-cell lung cancer, and a response rate of 78.8% on untreated extensive-stage small-cell lung cancer" 11/01/2001 - "The study drugs were administered to patients with non-Hodgkin's lymphoma according to the following schedule: amrubicin hydrochloride (100 mg/m2, body surface area), cyclophosphamide (750 mg/m2) and vincristine sulfate (1.4 mg/m2, a maximal dose of 2.0 mg/body) were administered intravenously on day one, while prednisolone (60 mg/m2/day) was administered orally on days 1 to 5. This cycle of treatment was repeated every three weeks in principle" Get all the results and reference details, order at left...
4.	Lymphoma (Lymphomas) 11/01/2001 - "In conclusion, these results indicate that amrubicin hydrochloride is effective in the treatment of patients with malignant lymphoma." 11/01/2001 - "Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma]" 11/01/2001 - "An early phase II multi-center collaborative study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, was conducted for malignant lymphoma at 12 institutions nationwide" 11/01/2001 - "Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma]" Get all the results and reference details, order at left...
5.	Lung Neoplasms (Lung Cancer) 10/01/2007 - "Further clinical trials will clarify the status of amrubicin in the treatment of lung cancer." 02/01/2006 - "Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer." 02/15/2008 - "Amrubicin is a completely synthetic 9-aminoanthracycline agent for the treatment of lung cancer in Japan" 11/01/2007 - "Although amrubicin hydrochloride (AMR) has promising activity against pretreated lung cancer, there are few reports on the adverse events of this agent in a clinical practice setting" 11/01/2007 - "Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients]" Get all the results and reference details, order at left...
31 Diseases and 59 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	irinotecan (Camptosar)
2.	Doxorubicin (Adriamycin)
3.	Cisplatin (Platino)
4.	Type II DNA Topoisomerases (Topoisomerase II)
5.	amrubicinol
6.	Topotecan (Hycamtin)
7.	Carboplatin (JM8)
8.	Vincristine (Oncovin)
9.	Prednisolone (Predate)
10.	Type I DNA Topoisomerases (Topoisomerase I)
33 Drugs and Important Bio-Agents and 38 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Renal Dialysis (Hemodialysis)
4 Therapies and Procedures and 19 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>